Introduction: Preneoplastic lesions of the bronchial tree have a high probability of developing into malignant tumors. Currently, the best method for localizing them for further treatment is a combined white light bronchoscopy (WLB) and autofluorescence bronchoscopy (AFB) (WLB ϩ AFB). The average specificity from large clinical trials for this combined detection method is approximately 60%, leading to many false positives. The object of this study is to determine whether adding point laser Raman spectroscopy (LRS) to a WLB ϩ AFB has the potential to improve the specificity of preneoplastic lesion detection and what the implication is to the detection sensitivity. Methods: An LRS system was developed to collect real-time, in vivo lung spectra with a fiber optic catheter passed down the instrument channel of a bronchoscope. WLB ϩ AFB imaging modalities were used to identify lesions from 26 subjects, from which 129 Raman spectra were measured. Multivariate statistical analyses were performed on the spectra with a leave-one-out crossvalidation. Results: Clear in vivo Raman spectra were obtained in 1 second. The location of individual Raman peaks in the spectra correlated well with the known positions of Raman peaks generated by lipids, proteins, and water molecules. Preneoplastic lesions were detected with a sensitivity of 96% and a specificity of 91%. Conclusion: Adding point LRS analysis to WLB ϩ AFB imaging has the ability to detect preneoplastic lesions in real time with high sensitivity and specificity. The use of LRS has great potential for substantially reducing the number of false-positive biopsies associated with WLB ϩ AFB with very little reduction in the detection sensitivity.
P reneoplastic lesions of the bronchial airways including moderate and severe dysplasia and carcinoma in situ have a high probability of developing into malignancies. 1, 2 Localizing these preneoplastic lesions during a bronchoscopy so that further treatment can be administered is key to increasing the patient's chances of survival. 3 In the 1990s, the adjunct use of autofluorescence bronchoscopy (AFB) with white light bronchoscopy (WLB) was developed and has made significant improvements to the localization of preneoplastic lesions. [3] [4] [5] [6] [7] [8] [9] [10] [11] The relative sensitivity from several single and multicenter clinical trials using AFB ϩ WLB for detecting preneoplasias was on average twofold larger (1.5-6.3) than WLB alone. Nevertheless, the average specificity of these trials was only 60%, which leads to many false-positive biopsies. [7] [8] [9] [10] [11] This suboptimal figure is partially dependent on the experience of the bronchoscopist to select which, out of the many, tissue sites identified with WLB ϩ AFB to biopsy. Nevertheless, the main reason for the high number of false positives is the low specificity inherent with AFB, because benign lesions (including inflammation) and preneoplastic lesions present with similar autofluorescence characteristics. Thus, there is still a great need for improved detection methods.
The advent of digital videoendoscopes has resulted in clearer images, and initial trials with them have produced promising sensitivity and specificity values for detecting preneoplasias when combined with AFB. 12 Preliminary results also show an added discriminatory benefit for preneoplastic lesions by combining narrow band imaging with AFB. 13 Nevertheless, neither of these methods have been tried in large scale, multicenter, clinical trials, and they still require subjective decision making by the bronchoscopist on which sites to biopsy. Presently, it is not clear what the best way forward will be. 14, 15 Laser Raman spectroscopy (LRS) is a technology that has not been explored to any great extent for in vivo characterization of lung lesions despite it being hailed as the optical modality with the most potential for detecting early tissue diseases. 16 LRS involves exposing the tissue to low-power laser light and collecting the scattered light for spectroscopic analyses. 16 It is a powerful technology because spectra are obtained nondestructively, and light scattered from samples with different molecular compositions can be easily differentiated. The uptake of Raman by the medical community has been slow though mainly due to the lack of equipment in the past sensitive enough to measure the weak Raman emission. Nowadays, equipment has advanced to the point where using Raman to detect early cancers and precancers in vivo is feasible. 17 Although fast in vivo Raman imaging is still not possible, and thus, it cannot be used by itself to rapidly localize diseased tissue, point Raman spectra would be helpful in reducing the number of false-positive biopsies if WLB ϩ AFB are first used to rapidly identify sites of concern. 18 The advantage is that the highly specific Raman spectrum would enable an instantaneous and objective measure of whether a lesion is preneoplastic, malignant, or neither. This will increase the specificity compared with WLB ϩ AFB alone without a large sacrifice in detection sensitivity and without overly prolonging procedure times.
In this study, we report on a pilot study conducted to test whether adding an in vivo Raman spectroscopy measurement to WLB ϩ AFB imaging can improve the specificity of detecting lesions with pathologies of moderate dysplasia or worse (ՆMOD) and at what cost to the detection sensitivity.
MATERIALS AND METHODS
Raman systems have been developed for in vivo measurements on several organs other than the lung. 19 -24 Initially, prospects looked good for adapting Raman for in vivo lung measurements as malignancies were identified in ex vivo tissue with a high sensitivity and specificity by ourselves 25 and others. 26 The preferred method of incorporating Raman into the lung clinic was to use the instrument channel of existing bronchoscopes. Nevertheless, a Raman catheter diameter of Յ2 mm was needed to fit the bronchoscope channel, which is much smaller than similar catheters designed for other organs 19 -24 which would severely limit the collection efficiency of the Raman emission. Furthermore, frequent and uncontrollable lung movements make it difficult to maintain the focus of the Raman catheter for more than a few seconds.
We overcame the restrictions to obtaining good quality in vivo Raman spectra of the lung 27 by using components to reduce fiber emission 28 and promote a high signal-to-noise ratio. 20 Our LRS system shown in Figures 1A, B , enabled real-time in vivo Raman measurements of the lung for the first time and with a short data acquisition time of 1 second. The traditional measurement range of 0 to 2000 cm Ϫ1 was abandoned because of the very strong lung tissue autofluorescence found by ourselves 27 and others 29 results in poor photon counting statistics for the simultaneously measured weak Raman. Instead, the 1500 to 3400 cm Ϫ1 range was used, which still contains significant biomolecular information but much less autofluorescence. 30 The system was mounted on a small cart and wheeled close to the subject for the procedure ( Figure 1C ).
The BC Cancer Agency Research Ethics Board approved the clinical test of the LRS system for the lung (certificate H06-00010). Subjects attending a bronchoscopy procedure as part of their medical care were invited to take part in the trial. The participants were current or former smokers older than 40 years who had smoked Ն20 packyears enrolled as part of a National Cancer Institute sponsored lung cancer chemoprevention trial (P01 CA096964) and patients suspected to have lung cancer who were scheduled for a diagnostic bronchoscopy at the British Columbia Cancer Agency. Informed patient consent was obtained. The procedure was for the bronchoscopist to identify lesions they would normally biopsy using combined WLB and AFB (Figures 2A, B) . Raman spectra were obtained from these sites ( Figure 2C ). Biopsies were taken of the same locations and classified by a pathologist. Eight classifications were used according to WHO criteria 31 : normal epithelium, hyperplasia (including goblet cell hyperplasia and basal/reserve cell hyperplasia), metaplasia (including immature squamous metaplasia and squamous metaplasia), mild dysplasia, moderate dysplasia, severe dysplasia, carcinoma in situ, and invasive squamous cell carcinoma (IC). The presence or absence of inflammatory changes was also recorded. Altogether 46 patients participated; of these, 26 were found to have suspicious areas with WLB ϩ AFB. One hundred twenty-nine Raman spectra were obtained: 51 of these were from sites with pathologies of ՆMOD, the rest were from sites with pathologies of mild dysplasia or better (ՅMILD).
The raw Raman spectra have to be standardized before they can be analyzed or compared with published spectra. 32 The procedure was to first subtract the ambient background signal from the raw data of each spectrum and then calibrate for the sensitivity of the system as a function of wavelength. The standardized procedure then continued in one of three different ways. In the first case (dataset A), each spectrum was smoothed (with a three-point moving average 33 ) to remove random noise and then normalized to reduce the effect of intensity variations from different tissue sites with the same pathology. The normalization was accomplished by summing the area under each curve and dividing each variable in the smoothed spectrum by this sum. In the second case (dataset B), each spectrum was also smoothed, but in this case, the autofluorescence was subtracted by a modified polynomial fitting routine 34 before normalization. The third method (dataset C) used a Savitzky-Golay 35 sixpoint quadratic polynomial on each spectrum to calculate a smoothed second-order derivative spectrum. Summing the squared derivative values of a spectrum and then dividing each variable by this sum was used for normalization.
Datasets A, B, and C were analyzed separately using statistical software (Statistica 6.0, StatSoft Inc., Tulsa, OK). Multivariate statistics were used, which compare whole spectra rather than single Raman peaks (univariate) as these have been shown be more accurate. 36 Principle components (PCs) for all the spectra in each dataset were computed to reduce the number of variables. Student's t tests were used on PCs that accounted for 0.1% or more of the variance to determine those most significant at separating spectra into two pathology groups: ՆMOD and ՅMILD. A linear discrimination analysis (LDA) with leave-one-out crossvalidation was used on the most significant PCs. To avoid over fitting the data, the number of PCs used in the LDA was limited to one third 17 of the total number of cases of the smallest subgroup, i.e., 51 ՆMOD spectra. The complete analyses of spectra from datasets A, B and C were redone a second time as described above except that all the spectra with IC pathology (24 in total) were dropped from each dataset (27 in total) . Spectra in each dataset remained with ՆMOD pathology classification, and thus, only nine PCs were used in the LDA crossvalidation model.
Raman spectra of reference materials that are the main contributors to emissions from human epithelia and connective tissues were obtained for comparison. These were DNA purified from a human placenta, RNA from baker's yeast, phenylalanine, tyrosine, tryptophan, triolein (an abundant lipid of the bronchial mucus 37 ), collagen from human lung, and human hemoglobin. Most reference samples were obtained from Sigma-Aldrich Canada Ltd. with the following reference numbers: DNA (D4642), RNA (R6750), phenylalanine (P2126), tyrosine (T3754), tryptophan (T0254), triolein (T7140), and human lung collagen (CH783). The hemoglobin was from the blood sample of a volunteer. The references were used neat in their supplied state without further processing. Spectra were obtained using the same equipment as the in vivo measurements by supporting the Raman catheter a few millimeters above the sample. The data were preprocessed in the same way as the in vivo data and then further processed as for dataset B spectra.
RESULTS
There was a substantial autofluorescence contribution to dataset A spectra, with relatively small Raman peaks around 1600, 2150, and 2900 cm Ϫ1 (Figure 3 ). The low intensity broad peak centered at 2150 cm Ϫ1 and the intense emission rising above 3100 cm Ϫ1 are assigned to water molecule vibrations. 38 Figure 4 shows in vivo spectra processed as dataset B; the Raman peaks seen in data set A spectra are now clearly visible. The broad peaks near 1663 cm Ϫ1 were most likely due to a combination of (C ϭ O) amide I vibrations 27 and 2 water molecule bending motions. 38, 39 The broad peak around 2900 cm Ϫ1 is assigned to a combination of lipid (C-H) peaks (2833 ϩ 2886 cm Ϫ1 ) and generic protein vibrations at 2938 cm Ϫ1 . There were other small peaks or shoulders in the spectra shown in Figure 4 at 1589, 1646, 1698, 1727, 2720, 2801, 2863, 2877, and 2921 cm Ϫ1 that are in agreement with the peaks of many amino acids, lipids, and proteins. 39, 40 Between 1750 and 2700 cm Ϫ1 of the emission range (not shown in Figure 4 ), there were a number of narrow peaks with very low intensities, apart from the broad emission at 2150 cm Ϫ1 , that did not seem to vary for different lung sites. This spectral region is not noted for any significant Raman peaks, although there are reports of some weak Raman emissions mainly due to carbon and nitrogen modes 39 that were in approximate agreement with some of the very low intensity peaks observed. Nevertheless, our data were too noisy in this region, probably due to residual optical fiber emissions 27 and small charge coupled device etaloning effects, 41 to be useful. Figure 5 shows the Raman spectra of some of the reference samples measured. The spectra have features consistent with those in the literature, see e.g., Movasaghi et al. 39 and references therein. Figure 6 shows the average Raman spectra of ՆMOD and ՅMILD lesions. The two mean spectra show significant differences (p Յ 0.05) at 13 wave number locations (indicated by vertical dashed lines in Figure 6 ). These locations correspond to either peaks or shoulders in the spectra. An approximate fit to each average spectrum was obtained with a least squares weighted sum of all the references measured. These fits showed relative increases in DNA, hemoglobin, phenylalanine, and triolein for ՆMOD lesions and a corresponding drop in collagen.
The second-derivative spectra of dataset C, over the ranges where significant differences (p Յ 0.05) between different pathology groups were apparent, are shown in Figure 7 .
The statistical analyses on spectra from datasets A, B and C led to significantly different results. Spectra from dataset A were the worst in predicting the pathology ՆMOD with 80% sensitivity and 72% specificity ( Table 1) . Removing the IC spectra from analyses resulted in a substantially worse sensitivity with only a modest increase in specificity. If spectra were only classified when the posterior probability was Ն0.7 or Յ0.3, then 80% sensitivity and 77% specificity were obtained at the cost of only being able to classify 99 of 129 spectra (77%).
Analyses of dataset B spectra showed an improvement in pathology prediction compared with dataset A spectra with 80% sensitivity and 79% specificity. Removing the IC spectra from analyses this time resulted in a substantially better specificity (89%) with the sensitivity unchanged. When using cutoff lines at 0.7 and 0.3, the sensitivity and specificity were 83% and 84%, respectively, and 80% of the 129 spectra were classified.
The best result was obtained by analyzing spectra processed with the second-order derivative (dataset C); 90% sensitivity and 91% specificity were obtained using all the spectra. In this case, only three IC spectra were misclassified (Figure 8 ). Dropping all the IC spectra from analyses resulted in the sensitivity increasing to 96% with the specificity unchanged at 91%, and when using the 0.7 and 0.3 cutoff lines, both sensitivity and specificity increased with 88% of spectra classified. The receiver operator characteristics for all the three datasets are shown in Figure 9 . One can clearly see the superiority of secondorder derivative processed spectra (dataset C). The fractional areas under each receiver operator characteristic curve were 0.78, 0.85, and 0.92 for spectra analyzed in datasets A, B, and C, respectively.
DISCUSSION
The maximum autofluorescence intensity was still significant over the measurement range used in this study, but it was an order of magnitude less than found over the traditional (fingerprint) range. 27 Furthermore, despite there being fewer Raman peaks in the measurement range, there were statistically significant differences in the spectra for sites with different pathologies. Although there did not seem to be any consistent trend in the changes to individual peaks (Figure 4) as the pathology of the tissue goes through the various FIGURE 6. Average spectra of dataset B processed data from sites with pathology ՅMILD (upper green curve) and ՆMOD (middle red curve). The two averages have been shifted on the intensity scale for clarity. The lower plot (blue curve) shows the result of subtracting the average ՅMILD spectra from the average ՆMOD spectra (not on the same intensity scale). The horizontal dashed line is at zero intensity. Two ranges (A and B) are shown as these were only where clear Raman peaks were observed. The vertical dashed lines are the wave numbers where the two averages had the most significant difference as determined by a t test statistic. Also shown (solid black curves) are the results of least square fit to the average spectra using a weighted linear combination of all the reference spectra measured. ՆMOD, lesions with pathology of moderate dysplasia or worse; ՅMILD, lesions with pathology of mild dysplasia or better. FIGURE 7. Average spectra of dataset C processed data from sites with pathology ՅMILD (upper green curve) and ՆMOD (middle red curve). The two averages have been shifted on the intensity scale for clarity. The lower plot (blue curve) shows the result of subtracting the average ՅMILD spectra from the average ՆMOD spectra (not on the same intensity scale). The horizontal dashed line is at zero intensity. Two ranges (A and B) are shown as these were only where clear Raman peaks were observed. ՆMOD, lesions with pathology of moderate dysplasia or worse; ՅMILD, lesions with pathology of mild dysplasia or better.
changes from normal to IC. This observation probably relates to the complex nonlinear biomolecular changes that occur demonstrating the needed for multivariate statistical analyses where the whole spectrum is used.
Although fitting the Raman spectra with a combination of reference spectra showed the expected biomolecular changes for diseased tissue, 25 the fits were not precise probably due to an insufficient number of references used. Refitting the spectra with an expanded set of reference spectra would be required to determine with more confidence which biomolecules have changed and by how much.
The statistical analyses of dataset A spectra were disappointing but not entirely unexpected. The site selection process was biased toward only selecting sites that were identified by the AFB imaging system algorithm, but it is known that this results in a less than optimal specificity. As it is generally not difficult to identify IC using a combination of WLB and AFB, dropping the IC spectra from the data analyses may improve detection of early stage disease. In the case of dataset A spectra, this reasoning proved false with only 55% of spectra from ՆMOD sites identified. The obvi-ous explanation for this is that autofluorescence dominates the spectra and that this autofluorescence is similar for all sites measured except those with IC.
The use of cutoff lines in analyses was in recognition of the fact that it was occasionally difficult to get good quality spectra. Patient involuntary movements were suspected as one cause of this problem, another was significant mucus or water on the tissue surface. It will be difficult to totally eliminate this problem, and thus, some real-time method of assessing the quality of a spectrum will be needed if Raman proves to be beneficial in a multicenter clinical trial. As the equipment is designed to work in the clinic, in real time, one possibility is to use cutoff lines to enable the bronchoscopist to immediately take another spectrum if the previous spectrum did not meet a tough statistical standard of being ՆMOD or ՅMILD. Any sites that failed after several attempts could be biopsied. The cutoff lines should not be made too strict; otherwise, this would defeat the object of decreasing the number of false positives. As a test, 0.7 and 0.3 posterior probability cutoffs were chosen for this pilot study, although for dataset A processed spectra, these only led to a 5% increase in specificity and no change in sensitivity. Analyses of dataset B spectra produced better results than dataset A, although there were some spectra from IC sites that were misclassified. The reason for this was most likely sampling errors, as IC lesions may contain areas other than the histologically malignant epithelium (i.e., desmoplatic stroma). Sampling of the adjacent reactive or inflamed nonneoplastic tissue is another possibility for the misclassified samples. Removing the IC spectra from analyses did increase the specificity by 9% with the sensitivity unchanged. Posterior probability cutoff lines made modest improvements to the sensitivity and specificity.
The second-order derivative spectra (dataset C) were the best at separating ՆMOD and ՅMILD tissue with 90% sensitivity and 91% specificity. Dropping the IC spectra sees the sensitivity rise by 6% with no loss in specificity. Apart from the IC spectra, the other misclassified sites were those with moderate dysplasia, mild dysplasia, metaplasia, and hyperplasia pathologies. Sampling errors may again explain these misclassifications. Although an alternative explanation for the misclassifications is that the Raman spectra contain biomolecular information, with no obvious histological counterpart, 11,42 on whether a lesion will develop into late-stage disease or not. More work is needed to test this theory.
It is not fully understood why processing data with a second-order derivative leads to the improvement observed in the sensitivity and specificity values. The major reason is thought to be that inaccuracies in the polynomial fitting of the substantial autofluorescence introduce an uncorrelated variance into dataset B. Other methods of removing the background fluorescence have been proposed such as shifted subtracted Raman spectroscopy, 26 but all have their advantages and disadvantages as explained by Zhao et al. 34 Their method works well for noncomplex background fluorescence and is fast for real-time clinical applications. Generating a derivative spectrum is also a fast process that can be done in the clinic in real time, and thus, this may be the optimal choice with intensely fluorescing tissue.
In conclusion, it seems that point LRS can significantly reduce the number of false-positive biopsies, whereas marginally reducing the sensitivity of WLB and AFB to the detection of preneoplastic lung lesions. Although it may be considered better to have a 40% false-positive rate than incur any loss in detection sensitivity, the slight loss incurred with the adjunct use of Raman may not be realized in practice. First, bronchoscopists currently have to make partially subjective decisions when using WLB ϩ AFB about which lesions to biopsy. The adjunct use of Raman would make the decision process more objective, which may result in the identification of additional preneoplastic lesions at sites initially rejected as biopsy candidates. Second, as mentioned earlier, Raman may be able to identify biomolecular changes in both histologically preneoplastic and nonpreneoplastic lesions that are markers for development into late-stage disease. If this proves to be correct, then the relative sensitivity of LRS ϩ WLB ϩ AFB for detecting premalignant lesions will actually increase compared with WLB ϩ AFB alone. More work is needed to follow-up on this pilot study and to test the conclusions we have arrived at, but the evidence so far points to Raman spectroscopy as having great potential for improving the early detection of preneoplastic lesions. 
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